20 years ago, MMRF Chief Scientific Officer George Mulligan was working as a translational researcher on a clinical trial for a drug candidate called “PS 341”. The hospitals whose patients were enrolled in the trial would share samples with George’s team. The data showed positive results in multiple myeloma patients that they had never seen before. That drug turned out to be Velcade and it was the beginning of a revolution in myeloma therapy. To this day, Dr. Mulligan feels a connection to the patients on that trial and it inspires his work at the MMRF to continue to make extraordinary things happen for the myeloma community. #25Voices #MMRF25

свернуть